Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Pancreatic Cancer peptide trials
4 selected ClinicalTrials.gov records carrying the official condition label Pancreatic Cancer. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
4 selected records.
4 profiles.
2020–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 113 selected PubMed records and 8 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Pancreatic Cancer unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT03404661
PeptideScanner retained ClinicalTrials.gov record NCT03404661 at 2026-11-16T01:34:15.953Z. Its registry update date was 2023-06-06, and PeptideScanner's reviewed identity mapping was secretin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- June 6, 2023
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04543071
PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- September 21, 2026
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01385956
PeptideScanner retained ClinicalTrials.gov record NCT01385956 at 2026-11-15T22:05:38.400Z. Its registry update date was 2020-09-28, and PeptideScanner's reviewed identity mapping was pasireotide.
- PeptideScanner change date
- November 15, 2026
- Cited source date
- September 28, 2020
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Motixafortide · 2026-09-21
ClinicalTrials.gov record NCT04543071
Active, not recruiting at the retained observation.
Open attributed record →Exenatide · 2026-08-04
ClinicalTrials.gov record NCT05663515
Recruiting at the retained observation.
Open attributed record →Secretin · 2023-06-06
ClinicalTrials.gov record NCT03404661
Completed at the retained observation.
Open attributed record →Pasireotide · 2020-09-28
ClinicalTrials.gov record NCT01385956
Completed at the retained observation.
Open attributed record →